Login Register Cart 0
Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Concept of Drug Metabolism in Drug Discovery Pipeline

Author(s): Syed Sayeed Ahmad and Mohammad A. Kamal

Volume 20, Issue 9, 2019

Page: [697 - 700] Pages: 4

DOI: 10.2174/138920022009191004112826

« Previous Next »
[1]
DiMasi, J.A.; Grabowski, H.G.; Hansen, R.W. Innovation in the pharmaceutical industry: New estimates of R&D costs. J. Health Econ., 2016, 47, 20-33.
[http://dx.doi.org/10.1016/j.jhealeco.2016.01.012] [PMID: 26928437]
[2]
Zhang, Z.; Tang, W. Drug metabolism in drug discovery and development. Acta Pharm. Sin. B, 2018, 8(5), 721-732.
[http://dx.doi.org/10.1016/j.apsb.2018.04.003] [PMID: 30245961]
[3]
Zhang, Z.; Zhu, M.; Tang, W. Metabolite identification and profiling in drug design: Current practice and future directions. Curr. Pharm. Des., 2009, 15(19), 2220-2235.
[http://dx.doi.org/10.2174/138161209788682460] [PMID: 19601824]
[4]
Coleman, M. Human Drug Metabolism: An Introduction, 1st ed; John Wiley & Sons: UK, 2010, pp. 13-18.
[http://dx.doi.org/10.1002/9780470689332.ch2]
[5]
Trunzer, M.; Faller, B.; Zimmerlin, A. Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation. J. Med. Chem., 2009, 52(2), 329-335.
[http://dx.doi.org/10.1021/jm8008663] [PMID: 19108654]
[6]
Madden, L.R.; Nguyen, T.V.; Garcia-Mojica, S.; Shah, V.; Le, A.V.; Peier, A.; Visconti, R.; Parker, E.M.; Presnell, S.C.; Nguyen, D.G.; Ret-ting, K.N. Bioprinted 3D primary human intestinal tissues model aspects of native physiology and ADME/Tox functions. iScience, 2018, 2, 156-167.
[7]
Wu, K.C.; Lin, C.J. The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age-related disorders. Yao Wu Shi Pin Fen Xi, 2019, 27(1), 48-59.
[http://dx.doi.org/10.1016/j.jfda.2018.11.005] [PMID: 30648594]
[8]
Kulkarni, A.; Han, Y.; Hopfinger, A.J. Predicting Caco-2 cell permeation coefficients of organic molecules using membrane-interaction QSAR analysis. J. Chem. Inf. Comput. Sci., 2002, 42(2), 331-342.
[http://dx.doi.org/10.1021/ci010108d] [PMID: 11911703]
[9]
Irvine, J.D.; Takahashi, L.; Lockhart, K.; Cheong, J.; Tolan, J.W.; Selick, H.E.; Grove, J.R. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J. Pharm. Sci., 1999, 88(1), 28-33.
[http://dx.doi.org/10.1021/js9803205] [PMID: 9874698]
[10]
König, J.; Müller, F.; Fromm, M.F. Transporters and drug-drug interactions: Important determinants of drug disposition and effects. Pharmacol. Rev., 2013, 65(3), 944-966.
[http://dx.doi.org/10.1124/pr.113.007518] [PMID: 23686349]
[11]
Meyer, U.A. Overview of enzymes of drug metabolism. J. Pharmacokinet. Biopharm., 1996, 24(5), 449-459.
[http://dx.doi.org/10.1007/BF02353473] [PMID: 9131484]
[12]
Xu, C.; Li, C.Y.; Kong, A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res., 2005, 28(3), 249-268.
[http://dx.doi.org/10.1007/BF02977789] [PMID: 15832810]
[13]
Almazroo, O.A.; Miah, M.K.; Venkataramanan, R. Drug metabolism in the liver. Clin. Liver Dis., 2017, 21(1), 1-20.
[http://dx.doi.org/10.1016/j.cld.2016.08.001] [PMID: 27842765]
[14]
Xie, F.; Ding, X.; Zhang, Q.Y. An update on the role of intestinal cytochrome P450 enzymes in drug disposition. Acta Pharm. Sin. B, 2016, 6(5), 374-383.
[http://dx.doi.org/10.1016/j.apsb.2016.07.012] [PMID: 27709006]
[15]
Hansen, J.; Palmfeldt, J.; Pedersen, K.W.; Funder, A.D.; Frost, L.; Hasselstrøm, J.B.; Jornil, J.R. Postmortem protein stability investigations of the human hepatic drug-metabolizing cytochrome P450 enzymes CYP1A2 and CYP3A4 using mass spectrometry., 2019, 194, 125-131.
[16]
Alam, Q. ZubairAlam, M.; Karim, S.; Gan, S.H.; Kamal, M.A.; Jiman-Fatani, A.; Damanhouri, G.A.; Abuzenadah, A.M.; Chaudhary, A.G.; Haque, A. A nanotechnological approach to the management of Alzheimer disease and type 2 diabetes. CNS Neurol. Disord. Drug Targets, 2014, 13(3), 478-486.
[http://dx.doi.org/10.2174/18715273113126660159] [PMID: 24059303]
[17]
Iqbal, A.; Ahmad, I.; Khalid, M.H.; Nawaz, M.S.; Gan, S.H.; Kamal, M.A. Nanoneurotoxicity to nanoneuroprotection using biological and computational approaches. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev., 2013, 31(3), 256-284.
[http://dx.doi.org/10.1080/10590501.2013.829706] [PMID: 24024521]
[18]
Tabrez, S.; Priyadarshini, M.; Urooj, M.; Shakil, S.; Ashraf, G.M.; Khan, M.S.; Kamal, M.A.; Alam, Q.; Jabir, N.R.; Abuzenadah, A.M.; Chaudhary, A.G.A.; Damanhouri, G.A. Cancer chemoprevention by polyphenols and their potential application as nanomedicine. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev., 2013, 31(1), 67-98.
[http://dx.doi.org/10.1080/10590501.2013.763577] [PMID: 23534395]
[19]
Jabir, N.R.; Tabrez, S.; Ashraf, G.M.; Shakil, S.; Damanhouri, G.A.; Kamal, M.A. Nanotechnology-based approaches in anticancer research. Int. J. Nanomedicine, 2012, 7, 4391-4408.
[PMID: 22927757]
[20]
Ahmad, M.Z.; Ahmad, J.; Amin, S.; Rahman, M.; Anwar, M.; Mallick, N.; Ahmad, F.J.; Rahman, Z.; Kamal, M.A.; Akhter, S. Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer’s disease. CNS Neurol. Disord. Drug Targets, 2014, 13(8), 1315-1324.
[http://dx.doi.org/10.2174/1871527313666141023100618] [PMID: 25345516]
[21]
Kamal, M.A. Editorial: Global trends for nanotechnological approaches in various health issues - Part 1. Curr. Drug Metab., 2015, 16(5), 334-335.
[http://dx.doi.org/10.2174/1389200216999150831130429] [PMID: 26321194]
[22]
Kamal, M.A. global trends in nanotechnological approaches for various health issues - Volume II. Curr. Drug Metab., 2015, 16(8), 598-601.
[http://dx.doi.org/10.2174/138920021608151107122016] [PMID: 26560319]

Rights & Permissions Print Cite
Article Metrics
29
4
1
1
© 2024 Bentham Science Publishers | Privacy Policy